April 24, 2025

Old Drug, New Trick for Joint Pain

Can a common diabetes drug double as a treatment for knee osteoarthritis?

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 22, 2025

AHA Framework Maps HF Prevention Strategy

“The growing morbidity, mortality, and health care costs related to heart failure underscore the urgent need to prioritize its primary prevention.”

Conexiant

April 22, 2025

Dual Therapy Lowers Death Risk in Diabetes Study

A large study found that combining GLP-1 receptor agonists with thiazolidinediones significantly reduced death and heart risks in patients with type 2 diabetes.

Conexiant

April 21, 2025

Audiometric Hearing Loss Major Dementia Risk

"Up to 32% of incident dementia cases could be attributable to clinically significant audiometric hearing loss," revealing the potential impact of treating hearing impairment for dementia prevention in older adults.

Conexiant

April 18, 2025

Montelukast Effective for Ulcerative Colitis, Study

Montelukast significantly improved remission maintenance in ulcerative colitis patients during corticosteroid tapering, reducing relapse rates and inflammatory markers.

Conexiant

April 18, 2025

Gallstone Recurrence Rates Post Nonoperative Management

"Delayed cholecystectomy should be prioritized for younger patients with a history of gallstone disease if early cholecystectomy is not feasible."

Conexiant

April 18, 2025

Weekly Semaglutide Boosts PAD Function: Study

Semaglutide significantly increased walking distance and improved symptoms and quality of life in patients with peripheral artery disease and type 2 diabetes over 52 weeks.

Conexiant

April 17, 2025

Oral Agent Shows Weight, A1c Drops

“As a convenient once-daily pill, orforglipron may provide a new option”—Lilly's oral GLP-1 agent showed up to 7.9% weight loss and HbA1c reductions in phase III diabetes trial.

Reuters